InVivo Therapeutics Appoints Lou Vaickus, MD as Interim Chief Medical Officer

  InVivo Therapeutics Appoints Lou Vaickus, MD as Interim Chief Medical

Business Wire

CAMBRIDGE, Mass. -- October 11, 2013

InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery company with a
focus on technologies for thetreatment of spinal cord injuries(SCI) and
neurotrauma conditions, today announced that Lou Vaickus, MD has been
appointed as interim Chief Medical Officer (CMO), effective October 15, 2013,
for a period of one year.

Currently, Dr. Vaickus is President of akta Pharmaceutical Development LLC.
Prior to that, he served as Vice President and Head, Clinical Development,
Global Medicines Development and Affairs at Vertex Pharmaceuticals. Before
joining Vertex, Dr. Vaickus was CMO of Tolerx, Inc. from 2002 to 2011.
Previously, he served as Senior Vice President, Medical Affairs and R&D at
Sunovion (formerly Sepracor) from 1998 to 2002, and as Medical Director at EMD
Serono (formerly Ares Serono) from 1993 to 1998. In these roles, Dr. Vaickus
successfully led the development of products in multiple therapeutic areas.

Michael Astrue, the interim CEO of InVivo, stated, “We are excited to have Dr.
Vaickus join us at this critical juncture in the company’s development. With
his judgment and experience, he will help us bring our scaffold product into
the clinic, he will help us define the best opportunities for our hydrogel
technology, and he will help us enter into the types of partnerships that
create value for a successful drug delivery company.”

Eric Woodard, MD will continue his longstanding relationship with InVivo as a
consultant and member of the Scientific Advisory Board.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. focuses on utilizing polymers as a platform
technology to develop treatments for serious diseases and conditions,
including improving function in individuals paralyzed as a result of traumatic
spinal cord injury. The Company was founded in 2005 with proprietary
technology co-invented by Robert Langer, ScD., Professor at Massachusetts
Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with
Massachusetts General Hospital. In 2011 the Company earned the David S. Apple
Award from the American Spinal Injury Association for its outstanding
contribution to spinal cord injury medicine. The publicly traded company is
headquartered in Cambridge, MA. For more details, visit,

Safe Harbor Statement

Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements within the meaning of the
federal securities laws. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks and
uncertainties, and include statements regarding the Company’s expectations
with respect to the commencement of human clinical trials for the scaffold
product and with respect to possible partnerships. The factors that could
cause actual future results to differ materially from current expectations
include, but are not limited to, risks and uncertainties relating to the
identification of appropriate clinical sites; the Institutional Review Board
process; the Company’s ability to enter into partnerships; the Company’s
ability to obtain FDA approval to commercialize its products; the Company’s
ability to develop, market and sell products based on its technology; the
expected benefits and efficacy of the Company’s products and technology in
connection with spinal cord injuries; the availability of substantial
additional funding for the Company to continue its operations and to conduct
research and development, clinical studies and future product
commercialization; and other risks associated with the Company’s business,
research, product development, regulatory approval, marketing and distribution
plans and strategies identified and described in more detail in our filings
with the SEC, including our Form 10-K and 10-Qs and our current reports on
Form 8-K. We do not undertake to update these forward-looking statements made
by us.


InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Director, Investor Relations
Press spacebar to pause and continue. Press esc to stop.